New research reveals that people who discontinue new slimming jabs like semaglutide or tirzepatide may regain lost weight much more quickly than those who end traditional lifestyle regimens.
Findings released in a prominent medical journal points out that while overweight people often shed substantial amounts of their body weight while undergoing treatment, the mass comes back at an average rate of nearly a kilo each month after stopping.
"Individuals purchasing these drugs need to be aware of the danger of rapid rebound weight gain when the medication is stopped," stated lead investigator Dr. Susan Jebb.
This pace of recovery implies a reversion to pre-treatment mass within about 18 months.
Comparing Approaches
The study, which examined dozens of studies involving over 9,000 of participants, compared the results of these new drugs with older methods.
The team note that individuals who shed pounds through lifestyle changes alone generally have a more gradual creep back—approximately 0.1 kg a month—post-intervention.
The Reason for the Quick Rebound
Nutrition scientists believe the mechanism of the injections is key to understanding the heightened rebound.
The injections copy a body's own chemical called GLP-1, which helps regulate appetite.
"Sustained high doses of GLP-1 levels several times higher than the body's typical production could lead to the body to produce less of its own natural hormone, and may also diminish sensitivity to its effects," explained Dr. Adam Collins, a nutrition researcher.
"Discontinuation of this hormone supplement results in hunger is unsuppressed, making binge eating a significant risk."
A Lifelong Issue?
The NHS advise the jabs for people with obesity-related health risks, accompanied by recommended diet and exercise modifications.
Many experts contend that, given the likelihood of relapse, the therapy should be considered life-long.
This perspective is supported by pharmaceutical companies, who note that the findings "emphasize the chronic nature of obesity," similar to managing conditions like high blood pressure.
User Testimonies
Individuals who have stopped the medication describe a sudden return of hunger.
"I experienced a trigger flipping and you become extremely hungry," recalled a patient.
The struggle is compounded if users have not established sustainable dietary or behavioural modifications during therapy.
Growing Adoption
Figures indicate that a significant number of adults in the UK have tried these injections in the past year, with demand continuing to grow.
- Adoption is greater among women than males.
- The 40s and 50s age group shows the greatest level of interest.
- Many obtain the drugs through private healthcare rather than public health services.
In conclusion, clinicians emphasize that while the jabs are potent tools for weight loss, they are not a magic fix and lasting health benefits hinges on combined lifestyle management.
